Abstract:Melanoma is known to be the most hazardous and life-threatening type of skin cancer. Although numerous treatments have been authorized in recent years, they often result in severe side effects and may not fully cure the disease. To combat this issue, immunotherapy has emerged as a promising approach for the prevention and treatment of melanoma. Specifically, the use of epitope melanoma vaccine, a subset of immunotherapy, has recently gained attention. The aim of this study was to create a multi-epitope melanoma vaccine using immunoinformatic methods. Two well-known antigens, NYESO-1 and MAGE-C2, were selected due to their strong immunogenicity and high expression in melanoma. To enhance the immunogenicity of the peptide vaccine, Brucella cell-surface protein 31 (BCSP31), the G5 domain of resuscitation-promoting factor B (RpfB) adjuvants, and the helper epitope of pan HLADR-binding epitope (PADRE) were incorporated to vaccine construct. These different segments were connected with suitable linkers and the resulting vaccine structure was evaluated for its physicochemical, structural, and immunological properties using computational tools. The designed vaccine was found to have satisfactory allergenicity, antigenicity, and physicochemical parameters. Additionally, a high-quality tertiary structure of the vaccine was achieved through modeling, refinement, and validation. Docking and molecular dynamics studies showed that the vaccine had a stable and appropriate interaction with the cognate TLR2 and TLR4 receptors during the simulation period. Finally, in silico immune simulation analysis revealed a significant increase in the levels of helper and cytotoxic T cells, as well as the cytokines interferon-gamma and interleukin-2, after repeated exposure to the melanoma vaccine. These results suggest that the designed vaccine has the potential to be an effective therapeutic option for melanoma. However, additional in vitro and in vivo validations are crucial to assess real-world efficacy and safety.

Strategies in DNA vaccine for melanoma cancer

mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients

Gold Nanocage-Based Photothermal Ablation Facilitates in Situ Vaccination for Melanoma Therapy.

Applications of Melanin and Melanin-Like Nanoparticles in Cancer Therapy: A Review of Recent Advances

Peptide nanovaccine in melanoma immunotherapy

Research Advances in the Treatment of Melanoma by Treat Melanoma.

Advancements in Melanoma Therapies: From Surgery to Immunotherapy

Immunoinformatic approach to design an efficient multi-epitope peptide vaccine against melanoma

Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma

Immunotherapy of Human Melanoma: Past, Present, Future

DNA vaccines to attack cancer

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

275. Immunostimulatory Antigen Loaded Microparticles As Cancer Vaccines

Advancements in melanoma immunotherapy: the emergence of Extracellular Vesicle Vaccines

Exosome-based immunotherapy as an innovative therapeutic approach in melanoma

Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential

Multifunctional Nanoparticle Approach for Targeting Melanoma

Targeted therapeutic strategies for melanoma

Exosome application in tumorigenesis: diagnosis and treatment of melanoma

Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View